Therakos® Cellex® Photopheresis System

The THERAKOS® CELLEX® Photopheresis System is indicated for use in the ultraviolet-A (UVA) irradiation, in the presence of the photoactive drug 8-methoxypsoralen (8-MOP), of extracorporeally circulating leukocyte-enriched blood, in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) and systemic sclerosis (SSc).

Please consult the product monograph for methoxsalen sterile solution (if used in conjunction with the THERAKOS® CELLEX® Photopheresis System) and the Operator’s Manual for the CELLEX by calling us at 1-877-566-9466 for contraindications, warnings, precautions, adverse reactions, interactions, and conditions of clinical use.

Customer Support

We will be in touch shortly

Here to support you


You are now leaving the Mallinckrodt Canada site

Users agree that access to and use of any website linked from this site and the content of either is at their own risk. Mallinckrodt Canada shall not be liable in any matter whatsoever for any direct, incidental, consequential, indirect or punitive damages arising from the access to, use of, or inability to use this website or any website linked to this site or for any errors or omissions in the content of either this website or any website linked to this site.